Verapamil-sensitive Ca2+ channel regulation of Th1-type proliferation of splenic lymphocytes induced by Walker 256 tumor development in rats

European Journal of Pharmacology

Volumn 549, Issue 1-3, 2006, Pages 179-184

  Degasperi, Giovanna R ^a   Zecchin, Karina G ^a   Borecký, Jiri ^a   Cruz Höfling, Maria A ^a   Castilho, Roger F ^a   Velloso, Lício A ^a   Guimarães, Fernando ^a   Vercesi, Anibal E ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Cancer; Immune response; L type Ca2+ channel; Verapamil; Walker 256 tumor

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL L TYPE; CYTOKINE; GAMMA INTERFERON; HEMOGLOBIN; INTERLEUKIN 10; VERAPAMIL; CALCIUM CHANNEL;

ANALYSIS; ANEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANOREXIA; ARTICLE; ASCITES TUMOR; CARCINOGENESIS; CD8+ T LYMPHOCYTE; CLINICAL FEATURE; CONTROL GROUP; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE EXACERBATION; DRUG SENSITIVITY; FOOD INTAKE; HEMOGLOBIN BLOOD LEVEL; IMMUNE RESPONSE; IMMUNOREGULATION; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; MALE; NONHUMAN; OBSERVATION; PRIORITY JOURNAL; PROPHYLAXIS; RAT; SPLEEN LYMPHOCYTE; SPLEEN SIZE; SPLENOMEGALY; TH1 CELL; TUMOR IMMUNITY; WALKER CARCINOMA; ANIMAL; CANCER TRANSPLANTATION; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; DRUG EFFECT; EATING; EXPERIMENTAL NEOPLASM; METABOLISM; ORGAN SIZE; PATHOLOGY; PHYSIOLOGY; SPLEEN; T LYMPHOCYTE; TIME; TUMOR CELL LINE; WESTERN BLOTTING; WISTAR RAT;

ANIMALS; BLOTTING, WESTERN; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELL PROLIFERATION; EATING; HEMOGLOBINS; INTERFERON TYPE II; INTERLEUKIN-10; MALE; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; ORGAN SIZE; RATS; RATS, WISTAR; SPLEEN; T-LYMPHOCYTES; TH1 CELLS; TIME FACTORS; VERAPAMIL;

EID: 33748967325     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.08.027     Document Type: Article

References (38)

1. Abbas A.K., Murphy K.M., and Sher A. Functional diversity of helper T lymphocytes. Nature 383 (1996) 787-793
2. Argilés J.M., Moore-Carrasco R., Fuster G., Busquets S., and Lopez-Soriano F.J. Cancer cachexia: the molecular mechanisms. Int. J. Biochem. Cell Biol. 35 (2003) 405-409
3. Bacon K.B., Westwick J., and Camp R.D. Potent and specific inhibition of IL-8-, IL-1 alpha-and IL-1 beta-induced in vitro human lymphocyte migration by calcium channel antagonists. Biochem. Biophys. Res. Commun. 165 (1989) 349-354
4. Blaheta R.A., Hailer N.P., Brude N., Wittig B., Leckel K., Oppermann E., Bachmann M., Harder S., Cinatl J., Scholz M., Bereiter-Hahn J., Weber S., Encke A., and Markus B.H. In vitro analysis of verapamil-induced immunosuppression: potent inhibition of T cell motility and lymphocytic transmigration through allogeneic endothelial cells. Transplantation 69 (2000) 588-597
5. Braunwald E. Mechanism of action of calcium-channel-blocking agents. N. Engl. J. Med. 307 (1982) 1618-1627
6. Coopman P.J., and Mueller S.C. The Syk tyrosine kinase: A new negative regulator in tumor growth and progression. Cancer Lett. 241 (2006) 159-173
7. Dabbagh K., and Lewis D.B. Toll-like receptors and T-helper-1/T-helper-2 responses. Curr. Opin. Infect. Dis. 16 (2003) 199-204
8. 2+. J. Bioenerg. Biomembranes 38 (2006) 1-10
9. Hokey D.A., Larregina A.T., Erdos G., Watkins S.C., and Falo Jr. L.D. Tumor cell loaded type-1 polarized dendritic cells induce Th1-mediated tumor immunity. Cancer Res. 65 (2005) 10059-10067
10. Kobayashi K., Kaneda K., and Kasama T. Immunopathogenesis of delayed-type hypersensitivity. Microsc. Res. Tech. 53 (2001) 241-245
11. Lagman R.L., Davis M.P., LeGrand S.B., and Walsh D. Common symptoms in advanced cancer. Surg. Clin. North Am. 85 (2005) 237-255
12. Lee K.S., and Tsien R.W. Mechanism of calcium channel blockade by verapamil, D600, diltiazem and nitrendipine in single dialysed heart cells. Nature 302 (1983) 790-794
13. Lewis R.S. Calcium signaling mechanisms in T lymphocytes. Annu. Rev. Immunol. 19 (2001) 497-521
14. Lima T.M., Lima M., Almeida D.C., Mendonça J.R., and Curi R. Cachexia induced by Walker 256 tumor growth causes rat lymphocyte death. Cancer Immuno. Immunother. 54 (2005) 179-186
15. Liu P., Li J., Han Z.C., Lu H., Wang Y., and Xu B. Elevated plasma levels of vascular endothelial growth factor is associated with marked splenomegaly in chronic myeloid leukaemia. Leuk. Lymphoma 46 (2005) 1761-1764
16. Michalek J., Buchler T., and Hajek R. T lymphocyte therapy of cancer. Physiol. Res. 53 (2004) 463-469
17. Miller G.M., Kim D.W., Andres M.L., Green L.M., and Gridley D.S. Changes in the activation and reconstitution of lymphocytes resulting from total-body irradiation correlate with slowed tumor growth. Oncology 65 (2003) 229-241
18. Ohl L., Bernhardt G., Pabst O., and Forster R. Chemokines as organizers of primary and secondary lymphoid organs. Semin. Immunol. 15 (2003) 249-255
19. Park H.H., Kim M., Lee B.H., Lim J., Kim Y., Lee E.J., Min W.S., Kang C.S., Kim W.I., Shim S.I., and Han K. Intracellular IL-4, IL-10, and IFN-gamma levels of leukemic cells and bone marrow T cells in acute leukemia. Ann. Clin. Lab. Sci. 36 (2006) 7-15
20. Putz G., Rosner A., Nuesslein I., Schmitz N., and Buchholz F. AML1 deletion in adult mice causes splenomegaly and lymphomas. Oncogene 25 (2006) 929-939
21. Rao A., Luo C., and Hogan P.G. Transcription factors of the NFAT family: regulation and function. Annu. Rev. Immunol. 15 (1997) 707-747
22. Rubin H. Cancer cachexia: its correlations and causes. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 5384-5389
23. 2+ antagonist-induced vasodilation. Intracellular actions. Circ. Res. 52 (1983) 137-142
24. + T cells. Annu. Rev. Immunol. 12 (1994) 635-673
25. Segura J.A., Barbero L.G., and Marquez J. Early tumor effect on splenic Th lymphocytes in mice. FEBS Lett. 414 (1997) 1-6
26. Shen H., Wiederhold M.D., and Ou D.W. The suppression of macrophage secretion by calcium blockers and adenosine. Immunopharmacol. Immunotoxicol. 17 (1995) 301-309
27. Szabo S.J., Sullivan B.M., Peng S.L., and Glimcher L.H. Molecular mechanisms regulating Th1 immune responses. Annu. Rev. Immunol. 21 (2003) 713-758
28. Teixeira-Carvalho A., Martins-Filho O.A., Andrade Z.A., Cunha-Mello J.R., Wilson R.A., and Correa-Oliveira R. The study of T-cell activation in peripheral blood and spleen of hepatosplenic patients suggests an exchange of cells between these two compartments in advanced human Schistosomiasis mansoni infection. Scand. J. Immunol. 56 (2002) 315-322
29. Temple J.J., and Stuckey W.J. Mechanisms contributing to the anemia associated with a localized solid tumor. Am. J. Med. Sci. 292 (1986) 277-281
30. Tesi R.J., Hong J., Butt K.M., Jaffe B.M., and McMillen M.A. In vivo potentiation of cyclosporine immunosuppression by calcium antagonists. Transplant. Proc. 19 (1987) 1382-1384
31. Tisdale M.J. Molecular pathways leading to cancer cachexia. Physiology (Bethesda) 20 (2005) 340-348
32. Triggle D.J. L-type calcium channels. Curr. Pharm. Des. 12 (2006) 443-457
33. Walus K.M., Fondacaro J.D., and Jacobson E.D. Effects of calcium and its antagonists on the canine mesenteric circulation. Circ. Res. 48 (1981) 692-700
34. Wang L., Devarajan E., He J., Reddy S.P., and Dai J.L. Transcription repressor activity of spleen tyrosine kinase mediates breast tumor suppression. Cancer Res. 65 (2005) 10289-10297
35. Wright B., Zeidman I., Greig R., and Poste G. Inhibition of macrophage activation by calcium channel blockers and calmodulin antagonists. Cell Immunol. 95 (1985) 46-53
36. Yamaki T., Uede T., and Kikuchi K. Cellular mechanisms of tumor rejection in rats. Nat. Immun. Cell Growth Regul. 9 (1990) 1-25
37. Yang A.S., and Lattime E.C. Tumor-induced interleukin 10 suppresses the ability of splenic dendritic cells to stimulate CD4 and CD8 T-cell responses. Cancer Res. 63 (2003) 2150-2157
38. Zecchin K.G., Pereira M.C., Coletta R.D., Graner E., and Jorge J. Ovariectomy reduces the gelatinolytic activity and expression of matrix metalloproteinases and collagen in rat molar extraction wounds. Calcif. Tissue Int. 76 (2005) 136-145